QVR’s Moderna MRNA Stock Holding History

QVR’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-830	Closed	-$119K	–	336
2022 Q2	$119K	Sell	830 -188	-18%	-$26.9K	0.01%	304
2022 Q1	$175K	Buy	+1,018	New	+$171K	0.01%	263
2021 Q4	–	Sell	-1,041	Closed	-$401K	–	205
2021 Q3	$401K	Buy	+1,041	New	+$384K	0.03%	254

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

QVR's MRNA Position: Q3 2022 in Review

QVR sold out of Moderna (MRNA) in Q3 2022, closing a stake of 830 shares — an estimated $119K sold.

QVR first reported a position in MRNA in Q3 2021 and held it in 3 quarters. The position peaked at $401K in Q3 2021. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

QVR reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
QVR sold 830 Moderna shares in Q3 2022, an estimated $119K.
QVR first reported a position in Moderna in Q3 2021 and held it in 3 quarters.
QVR's Moderna position peaked at $401K in Q3 2021.
915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on QVR's 13F filing for Q3 2022, filed 25 Oct 2022.